Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Furosemide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gerresheimer: FDA grants Tentative Approval of SQ Innovation's Lasix® ONYU*
Details : Lasix ONYU (furosemide) is a sodium-(potassium)-chloride cotransporter 2 inhibbitor, indicated in adults & pediatric patients for the treatment of edema associated with heart failure.
Product Name : Lasix ONYU
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2024
Lead Product(s) : Furosemide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Furosemide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Device and Drug Combination Could Revolutionize Heart Failure Treatment
Details : Lasix ONYU (furosemide) is a sodium-(potassium)-chloride cotransporter 2 inhibbitor, being evaluated in adults & pediatric patients for the treatment of edema associated with heart failure.
Product Name : Lasix ONYU
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 27, 2023
Lead Product(s) : Furosemide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable